Physiotherapy Using Vagal Stimulation with Trigger Point Release as Additional Treatment for Mild Preeclampsia in Pregnant Women Combined with Personalized Blood Pressure Medication

What this Trial Is About

Preeclampsia is a common and serious pregnancy complication marked by high blood pressure, affecting both mother and baby, and contributing to significant maternal and perinatal deaths worldwide. This trial evaluates a non-invasive, complementary therapy called vagal autonomic stimulation physiotherapy using trigger point release, combined with standard antihypertensive treatment. The study aims to see if this approach can improve blood pressure control and overall health outcomes in pregnant women with mild preeclampsia. Participants will be randomly assigned to two groups one receiving vagal stimulation physiotherapy with trigger point release every two weeks alongside personalized antihypertensive medication, and the other receiving positional release therapy with the same medication schedule. Both therapies involve physiotherapy sessions targeting the nervous system to aid blood pressure regulation. Treatment continues from the start of the study until 4 to 5 weeks after obstetric resolution. Throughout the study, participants blood pressure and heart rate will be monitored every two weeks from baseline until about a month after delivery. Researchers will also assess biochemical markers related to kidney and liver function, blood counts, cholesterol levels, inflammation, and blood clotting. The trial will last approximately 12 months, focusing on evaluating the safety and effectiveness of the vagal stimulation therapy as an adjunct to standard care.

Vagal Stimulation Therapy and Preeclampsia